Pharmacokinetics of Dihydroartemisinin-Piperaquine in the Treatment of Uncomplicated Malaria in Children in Burkina Faso
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Feb 17, 2009
Trial Information
Current as of June 15, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Positive screening thick blood smear
- • 2. Fever (\> 37.5ºC axillary) or history of fever in the previous 24 hours
- • 3. Age ≥ 6 months to 10 years
- • 4. Weight \> 5 kg
- • 5. Absence of any history of serious side effects to study medications
- • 6. No evidence of a concomitant febrile illness in addition to malaria
- • 7. No history of antimalarial use in the previous two weeks
- • 8. P. falciparum mono-infection
- • 9. Parasite density 2000-200,000/ul
- • 10. Provision of informed consent and ability to participate in 42-day follow-up
- Exclusion Criteria:
- • 1. Danger signs or evidence of severe malaria
- • 2. Hemoglobin levels \< 5.0 gm/dL
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Sunil Parikh, M.D., M.P.H.
Principal Investigator
University of California, San Francisco
Philip J Rosenthal, M.D.
Principal Investigator
University of California, San Francsico
Jean-Bosco Ouedraogo, M.D., PhD
Principal Investigator
Institut de Receherche en Sciences de la Sante Bobo-Dioulasso
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials